A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 679 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Larger NGS Gene Panel Linked to More Clinical Utility October 16, 2020 PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative... November 10, 2025 A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk... March 23, 2022 COVID-19 Takes the Life of a Widowed Mother of 6 Who... March 20, 2020 Load more HOT NEWS Understanding the Risk of Second Cancers After CAR T-Cell Therapy FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes
